CORRECTION -- Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy
September 21, 2022 11:08 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on August 2, 2022 by Marius Pharmaceuticals, please note that the correct number for reporting side...
Seraxis Announces Appointment of Chief Medical Officer, Dr. Paul Strumph
August 30, 2022 06:45 ET | Seraxis, Inc.
GERMANTOWN, Md., Aug. 30, 2022 (GLOBE NEWSWIRE) -- The regenerative medicine company Seraxis Inc. today announced the appointment of Paul Strumph, M.D. as Chief Medical Officer. Dr. Strumph is an...
TIP_link_300x300.jpg
Point-of-Care Molecular Diagnostics Market Size ($5,381.18Mn by 2028) Lead by Assays and Kits (13.4% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 29, 2021 13:28 ET | The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Point-of-Care Molecular Diagnostics Market: Key InsightsAccording to our new research study on Point-of-Care Molecular Diagnostics Market Size and...
crinetics.png
Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint
October 26, 2020 07:02 ET | Crinetics Pharmaceuticals, Inc.
ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy   Paltusotine was observed to be well tolerated among...
crinetics.png
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
September 21, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals to Participate in September Investor Conferences
September 03, 2020 17:56 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and...
Reports and Data.jpeg-01
Immunoassay Analyzers Market To Reach USD 26.40 Billion By 2027 | Reports and Data
August 27, 2020 17:00 ET | Reports and Data
New York, Aug. 27, 2020 (GLOBE NEWSWIRE) -- The Global Immunoassay Analyzers market is forecast to reach USD 26.40 Billion by 2027, according to a new report by Reports and Data. Immunoassay...
crinetics.png
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 07, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolled patients in the ongoing Phase 2 ACROBAT Edge clinical trial for paltusotine had completed the study...
crinetics.png
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 17, 2020 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 17, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
April 15, 2020 00:21 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...